1-aminocyclohexane derivatives for the treatment of hearing loss

Patent metadata

Field	Value
Publication number	US-9468610-B2
Application number	US-73358208-A
Country	US
Kind code	B2
Filing date	Sep 10, 2008
Priority date	Sep 12, 2007
Publication date	Oct 18, 2016
Grant date	Oct 18, 2016

Abstract

The present invention relates to the treatment of an individual diagnosed with hearing loss comprising administering to the individual an effective amount of a 1-amino-alkylcyclohexane derivative.

First claim

The invention claimed is:

1. A method of treating hearing loss in a subject in need thereof, comprising oral administration of a 1-aminocyclohexane derivative selected from the group consisting of neramexane and pharmaceutically acceptable salts thereof, wherein the 1-aminocyclohexane derivative is administered at a dose of about 50 mg/day, and wherein treatment results in alleviation of at least one symptom of hearing loss.

2. The method of claim 1 , wherein the hearing loss is selected from mild hearing loss, moderate hearing loss, severe hearing loss, profound hearing loss, and deafness.

3. The method of claim 1 , wherein the hearing loss is selected from acoustic trauma, noise-induced hearing loss, sensorineural hearing loss, mixed hearing loss, unspecified hearing loss, ototoxic hearing loss, drug-induced hearing loss, environmental chemicals-induced hearing loss, cancer-induced hearing loss, surgical-induced hearing loss, radiation-induced hearing loss, infection-induced hearing loss, sudden (idiopathic) hearing loss, auditory processing disorder, and presbycusis.

4. The method of claim 1 , wherein the 1-amino-alkylcyclohexane derivative is neramexane mesylate.

5. The method of claim 1 , wherein neramexane or a pharmaceutically acceptable salt thereof is administered once a day, twice a day (b.i.d.), or three times a day.

6. The method of claim 5 , wherein neramexane or a pharmaceutically acceptable salt thereof is administered twice a day.

7. The method of claim 1 , wherein neramexane or a pharmaceutically acceptable salt thereof is administered in an immediate release formulation.

8. The method of claim 1 , wherein neramexane or a pharmaceutically acceptable salt thereof is administered in a modified release formulation.

9. A method of treating hearing loss in a subject in need thereof, comprising oral administration a 1-aminocyclohexane derivative selected from the group consisting of neramexane and pharmaceutically acceptable salts thereof, wherein the 1-aminocyclohexane derivative is administered at a dose of about 50 mg/day, and an additional pharmaceutical agent which has been shown to be effective in treating hearing loss, wherein treatment results in alleviation of at least one symptom of hearing loss.

10. The method of claim 9 , wherein the 1-amino-alkylcyclohexane derivative is neramexane mesylate.

Assignees

• Kruger Hagen
• Merz Pharma Gmbh & Co Kgaa

Inventors

• Kruger Hagen

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P25/00

  Drugs for disorders of the nervous system · CPC title

• A61P27/00

  Drugs for disorders of the senses · CPC title

• A61P27/16

  Otologicals · CPC title

• A61P1/08

  for nausea, cinetosis or vertigo; Antiemetics · CPC title